Citius Oncology

Citius Oncology is a Cranford, New Jersey-based biopharmaceutical company developing and commercializing innovative targeted oncology therapies, with its lead asset LYMPHIR (denileukin diftitox-cxdl), a targeted immune therapy for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) that received FDA approval in August 2024 and was launched commercially in December 2025. Citius Oncology reported fiscal second quarter 2026 (calendar Q1 2026) financial results on May 15, 2026 (Form 8-K accession 0001213900-26-048629), with $1.7 million in net product revenue for the quarter, $5.6 million in net revenue for the first half of fiscal 2026 representing only four months of commercial LYMPHIR sales, gross margins of approximately 80%, broad payer coverage with no reimbursement denials, 83% of target accounts on formulary or in review, and up to $36.5 million in debt and equity capital secured. Cash runway extends only into November 2026 per third-party analysis, creating ongoing dilution overhang against the LYMPHIR commercial proof-out. DilutionWatch scores CTOR a 71/100 HIGH dilution risk.